Piper Sandler reiterates Overweight rating on HeartFlow, $64 price target

Several biotech stocks reached 52-week highs on September 18, 2026. Vogenx (VOGX) shares surged to $38.41, driven by positive clinical trial results. HeartSciences (HSCS) rose 7% to $5.21, while HeartFlow (HTFL) increased 2% to $52.22. Freenome (FRNM) gained 5% to $17.25, and Halozyme (HALO) hit $112.66 after announcing a $1.3B offering.

HeartFlow (HTFL) stock rose 9.63% after Q2 earnings beat and raised 2026 revenue outlook. Q2 revenue was $64.08M with 80.1% gross margin, but -55.8% profit margin. Company has strong liquidity with $162.55M cash and low debt. Analysts see near-term support at $46-$47 and resistance at $54-$56, with a 12-month target of $60 if growth continues.

HeartFlow (HTFL) shares rose after the company raised its full-year revenue targets. Revenue grew 48% YoY to $64.1M in Q2, with adjusted gross margin increasing to 83.3%. The company now expects 40-42% revenue growth for 2026, up from prior forecasts. CEO John Farquhar cited improved operating leverage and scalability.

Heartflow (HTFL) reported Q2 revenue of $64.1M, up 48% year over year, driven by higher U.S. FFRCT and Plaque case volumes. Gross margin rose to 83.0%. Net operating loss widened to $17.9M. The company raised FY26 revenue guidance to $246M-$250M and adjusted gross margin to about 82%.

Heartflow Inc. (NASDAQ:HTFL) rose about 46% week-on-week after reporting Q2 revenue up 48% to $64.08 million. Net loss widened to $15.7 million. For 2026, the company raised revenue growth guidance to 40% to 42%, or $246 million to $250 million. Stifel and JPMorgan lifted price targets to $45; Wells Fargo raised to $39.

HeartFlow (HTFL) shares rose 35.7% to $42.08 in the first full session after earnings. In Q2 2026, revenue was $64.1m (up from $43.4m), while net loss widened to $15.7m. Management lifted full-year revenue guidance to $246m to $250m and non-GAAP gross margin improved to 83.3%.